Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Colorectal Neoplasms

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 365 articles:
HTML format

Single Articles

    April 2024
  1. SOOMRO MY, Khan SR, Muhammad H, Ahmad S, et al
    Exploring treatment outcomes in Stage II-III rectal cancer patients undergoing neoadjuvant therapy at a tertiary care center in Pakistan: a comprehensive analysis of pathological outcomes.
    BMC Cancer. 2024;24:479.
    PubMed     Abstract available

  2. LI Y, Chen Z, Tian S, Han X, et al
    Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
    BMC Cancer. 2024;24:481.
    PubMed     Abstract available

  3. WADDELL O, Pearson J, McCombie A, Marshall H, et al
    The incidence of early onset colorectal cancer in Aotearoa New Zealand: 2000-2020.
    BMC Cancer. 2024;24:456.
    PubMed     Abstract available

  4. ELEZ E, Cubillo A, Alfonso PG, Middleton MR, et al
    Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    BMC Cancer. 2024;24:446.
    PubMed     Abstract available

  5. HUANG Y, Chen D, Bai Y, Zhang Y, et al
    ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
    BMC Cancer. 2024;24:452.
    PubMed     Abstract available

  6. CHEN H, Wang C, Chen Z, Huang T, et al
    The depth of perineural invasion is an independent prognostic factor for stage II colorectal cancer.
    BMC Cancer. 2024;24:433.
    PubMed     Abstract available

  7. TIAN Y, Wang Y, Wen N, Wang S, et al
    Prognostic factors associated with early recurrence following liver resection for colorectal liver metastases: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:426.
    PubMed     Abstract available

  8. XIAO Y, Wen X, Ying Y, Zhang X, et al
    Correlation between spleen density and prognostic outcomes in patients with colorectal cancer after curative resection.
    BMC Cancer. 2024;24:425.
    PubMed     Abstract available

  9. GHOFRANI-SHAHPAR M, Pakravan K, Razmara E, Amooie F, et al
    Cancer-associated fibroblasts drive colorectal cancer cell progression through exosomal miR-20a-5p-mediated targeting of PTEN and stimulating interleukin-6 production.
    BMC Cancer. 2024;24:400.
    PubMed     Abstract available

    March 2024
  10. LEE KH, Yang IJ, Ha GW, Lee J, et al
    mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.
    BMC Cancer. 2024;24:397.
    PubMed     Abstract available

  11. MAHDI-ESFERIZI R, Shiasi Z, Heidari R, Najafi A, et al
    Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer.
    BMC Cancer. 2024;24:371.
    PubMed     Abstract available

  12. STORM KS, Astrom LM, Sibolt P, Behrens CP, et al
    ROAR-A: re-optimization based Online Adaptive Radiotherapy of anal cancer, a prospective phase II trial protocol.
    BMC Cancer. 2024;24:374.
    PubMed     Abstract available

  13. DING H, Lin J, Xu Z, Wang HHX, et al
    The association between organised colorectal cancer screening strategies and reduction of its related mortality: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:365.
    PubMed     Abstract available

  14. LIN T, Zhang S, Tang Y, Xiao M, et al
    ART1 knockdown decreases the IL-6-induced proliferation of colorectal cancer cells.
    BMC Cancer. 2024;24:354.
    PubMed     Abstract available

  15. MATHUR S, Srivastava P, Srivastava A, Rai NK, et al
    Regulation of metastatic potential by drug repurposing and mitochondrial targeting in colorectal cancer cells.
    BMC Cancer. 2024;24:323.
    PubMed     Abstract available

  16. XIA S, Li Q, Zhu HT, Zhang XY, et al
    Fully semantic segmentation for rectal cancer based on post-nCRT MRl modality and deep learning framework.
    BMC Cancer. 2024;24:315.
    PubMed     Abstract available

  17. DUAN J, Zhu L, Shi Y, Wang W, et al
    Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study.
    BMC Cancer. 2024;24:302.
    PubMed     Abstract available

  18. HUANG JX, Zhang X, Tang M, Zhang Q, et al
    Comprehensive evaluation of serum hepatic proteins in predicting prognosis among cancer patients with cachexia: an observational cohort study.
    BMC Cancer. 2024;24:293.
    PubMed     Abstract available

    February 2024
  19. SONG M, Zhou X, Hou R, Sigdel M, et al
    CT-guided radioactive (125)I seeds brachytherapy for lung oligometastases from colorectal cancer: initial results.
    BMC Cancer. 2024;24:265.
    PubMed     Abstract available

  20. LIU Y, Hu X, Huang Y, Yin X, et al
    Does transanal drainage tubes placement have an impact on the incidence of anastomotic leakage after rectal cancer surgery? a systematic review and meta-analysis.
    BMC Cancer. 2024;24:263.
    PubMed     Abstract available

  21. JIN Y, Jiang A, Sun L, Lu Y, et al
    Long noncoding RNA TMPO-AS1 accelerates glycolysis by regulating the miR-1270/PKM2 axis in colorectal cancer.
    BMC Cancer. 2024;24:238.
    PubMed     Abstract available

  22. WANG B, Ling D, Li L, Zhang J, et al
    Impact of preoperative white blood cell count on outcomes in different stage colorectal cancer patients undergoing surgical resection: a single-institution retrospective cohort study.
    BMC Cancer. 2024;24:242.
    PubMed     Abstract available

  23. SCHOCKEL L, Woischke C, Surendran SA, Michl M, et al
    PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil.
    BMC Cancer. 2024;24:234.
    PubMed     Abstract available

  24. TANG Y, Liu Y, Wang X, Guo H, et al
    OLFM2 promotes epithelial-mesenchymal transition, migration, and invasion in colorectal cancer through the TGF-beta/Smad signaling pathway.
    BMC Cancer. 2024;24:204.
    PubMed     Abstract available

  25. HITCHCOCK KE, Miller ED, Shi Q, Dixon JG, et al
    Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (
    BMC Cancer. 2024;24:201.
    PubMed     Abstract available

  26. JIANG Y, Zhao M, Tang W, Zheng X, et al
    Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:188.
    PubMed     Abstract available

  27. GEHR NL, Karlsson P, Timm S, Christensen S, et al
    Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    BMC Cancer. 2024;24:168.
    PubMed     Abstract available

  28. FURUYA K, Nakajima M, Tsunedomi R, Nakagami Y, et al
    High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
    BMC Cancer. 2024;24:165.
    PubMed     Abstract available

  29. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    PubMed     Abstract available

  30. MEHRJOEI B, Haghnazari L, Bashiri H, Rezvani N, et al
    The diagnostic potential of miR-196a-1 in colorectal cancer.
    BMC Cancer. 2024;24:162.
    PubMed     Abstract available

    January 2024
  31. ALLAM AR, Elsayed MA, Daghash IT, Abdelaziz AM, et al
    Colonoscopy screening for colorectal cancer in Egypt: a nationwide cross-sectional study.
    BMC Cancer. 2024;24:131.
    PubMed     Abstract available

  32. XIE Z, Chen Q, Feng B, Jiang Y, et al
    Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China.
    BMC Cancer. 2024;24:115.
    PubMed     Abstract available

  33. TASCI ES, Oyan B, Sonmez O, Mutlu AU, et al
    Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    BMC Cancer. 2024;24:114.

  34. SIER MAT, Gielen AHC, Tweed TTT, van Nie NC, et al
    Accelerated enhanced recovery after colon cancer surgery with discharge within one day after surgery: a systematic review.
    BMC Cancer. 2024;24:102.
    PubMed     Abstract available

  35. TERLOUW D, Boot A, Ducarmon QR, Nooij S, et al
    Enrichment of colibactin-associated mutational signatures in unexplained colorectal polyposis patients.
    BMC Cancer. 2024;24:104.
    PubMed     Abstract available

  36. TAKASU C, Morine Y, Yoshikawa K, Nakao T, et al
    Role of stromal PD-L1 expression in colorectal liver metastasis.
    BMC Cancer. 2024;24:97.
    PubMed     Abstract available

  37. PECQUEUX M, Bruckner F, Oehme F, Hempel S, et al
    Preoperative IL-8 levels as prognostic indicators of overall survival: an extended follow-up in a prospective cohort with colorectal liver metastases.
    BMC Cancer. 2024;24:90.
    PubMed     Abstract available

  38. YANG C, Zhang Y, Yan M, Wang J, et al
    Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28.
    BMC Cancer. 2024;24:64.
    PubMed     Abstract available

  39. LIN P, Qian J, Huang CC, Xu WM, et al
    RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP.
    BMC Cancer. 2024;24:71.
    PubMed     Abstract available

  40. HUANG CY, Bai MH, Shen JW, Sun QQ, et al
    Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    BMC Cancer. 2024;24:57.
    PubMed     Abstract available

  41. AZZANI M, Azhar ZI, Ruzlin ANM, Wee CX, et al
    Subjective and objective financial toxicity among colorectal cancer patients: a systematic review.
    BMC Cancer. 2024;24:40.
    PubMed     Abstract available

  42. TASCI ES, Oyan B, Sonmez O, Mutlu AU, et al
    Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
    BMC Cancer. 2024;24:16.
    PubMed     Abstract available

  43. CHEN Y, Liu F, Chen X, Li W, et al
    microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation.
    BMC Cancer. 2024;24:26.
    PubMed     Abstract available

  44. QU W, Liu Z, Chen X, Liu B, et al
    Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
    BMC Cancer. 2024;24:22.
    PubMed     Abstract available

    December 2023
  45. NAKASHIMA M, Li K, Chen Q, de Silva S, et al
    Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.
    BMC Cancer. 2023;23:1268.
    PubMed     Abstract available

  46. SMITS LJH, van Lieshout AS, Debets S, Spoor S, et al
    Patients' perspectives and the perceptions of healthcare providers in the treatment of early rectal cancer; a qualitative study.
    BMC Cancer. 2023;23:1266.
    PubMed     Abstract available

  47. SUWATTHANARAK T, Tanjak P, Suwatthanarak T, Acharayothin O, et al
    Exploring extracellular matrix and prostaglandin pathway alterations across varying resection margin distances of right-sided colonic adenocarcinoma.
    BMC Cancer. 2023;23:1202.
    PubMed     Abstract available

  48. ZHANG X, Yuan H, Tan Z, Li G, et al
    Long-term outcomes of single-incision plus one-port laparoscopic surgery versus conventional laparoscopic surgery for rectosigmoid cancer: a randomized controlled trial.
    BMC Cancer. 2023;23:1204.
    PubMed     Abstract available

  49. MENS DM, van Rees JM, Wilting SM, Verhoef C, et al
    Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol.
    BMC Cancer. 2023;23:1187.
    PubMed     Abstract available

  50. CAI YX, Wu YQ, Liu J, Pan H, et al
    Proteome-wide analysis reveals potential therapeutic targets for Colorectal cancer: a two-sample mendelian randomization study.
    BMC Cancer. 2023;23:1188.
    PubMed     Abstract available

  51. WALDMANN A, Borchers P, Katalinic A
    Temporal trends in age- and stage-specific incidence of colorectal adenocarcinomas in Germany.
    BMC Cancer. 2023;23:1180.
    PubMed     Abstract available

    November 2023
  52. YU S, Cheng J, Li P, Tian L, et al
    Association study for the role of MMP8 gene polymorphisms in Colorectal cancer susceptibility.
    BMC Cancer. 2023;23:1169.
    PubMed     Abstract available

  53. CHENG Y, Yang X, Liang L, Xin H, et al
    Elevated expression of CXCL3 in colon cancer promotes malignant behaviors of tumor cells in an ERK-dependent manner.
    BMC Cancer. 2023;23:1162.
    PubMed     Abstract available

  54. LUO MR, Cai TN, Lu JL, Liu ZH, et al
    Regular gastroscopy and colonoscopy during the evaluation of urachal cancer: do we really need them?
    BMC Cancer. 2023;23:1156.
    PubMed     Abstract available

  55. LU X, Li Y, Li Y, Zhang X, et al
    Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1117.
    PubMed     Abstract available

  56. CHUNG Y, Nam SK, Chang HE, Lee C, et al
    Evaluation of an eight marker-panel including long mononucleotide repeat markers to detect microsatellite instability in colorectal, gastric, and endometrial cancers.
    BMC Cancer. 2023;23:1100.
    PubMed     Abstract available

  57. GUAN B, Xu M, Zheng R, Guan G, et al
    Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.
    BMC Cancer. 2023;23:1099.
    PubMed     Abstract available

  58. DONG Y, Zheng M, Wang X, Yu C, et al
    High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
    BMC Cancer. 2023;23:1097.
    PubMed     Abstract available

  59. JIA L, Liao L, Jiang Y, Hu X, et al
    Correction: Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression.
    BMC Cancer. 2023;23:1094.

  60. RENGGANATEN V, Huang CJ, Wang ML, Chien Y, et al
    Circular RNA ZNF800 (hsa_circ_0082096) regulates cancer stem cell properties and tumor growth in colorectal cancer.
    BMC Cancer. 2023;23:1088.
    PubMed     Abstract available

  61. WATANABE D, Fujii H, Ohata K, Iihara H, et al
    Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
    BMC Cancer. 2023;23:1078.
    PubMed     Abstract available

  62. LIU B, Zheng X, Li J, Yao P, et al
    Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRbeta/NF-kappaB signaling pathway.
    BMC Cancer. 2023;23:1070.
    PubMed     Abstract available

  63. KANG MK, Park SY, Park JS, Kim HJ, et al
    Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
    BMC Cancer. 2023;23:1059.
    PubMed     Abstract available

    October 2023
  64. JIA L, Liao L, Jiang Y, Hu X, et al
    Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression.
    BMC Cancer. 2023;23:1042.
    PubMed     Abstract available

  65. WANG Y, Jia Z, Wang Q, Zhu Z, et al
    Amino acids and risk of colon adenocarcinoma: a Mendelian randomization study.
    BMC Cancer. 2023;23:1041.
    PubMed     Abstract available

  66. BUCHWALD DS, Bassett DR, Van Dyke ER, Harris RM, et al
    "Sorry for laughing, but it's scary": humor and silence in discussions of Colorectal Cancer with Urban American Indians.
    BMC Cancer. 2023;23:1036.
    PubMed     Abstract available

  67. ZHANG Y, He S, Yu L, Shi C, et al
    Prognostic significance of HLA-G in patients with colorectal cancer: a meta-analysis and bioinformatics analysis.
    BMC Cancer. 2023;23:1024.
    PubMed     Abstract available

  68. ZHANG C, Zhang L, Tian Y, Guan B, et al
    Association between metabolic syndrome and early-stage colorectal cancer.
    BMC Cancer. 2023;23:1020.
    PubMed     Abstract available

  69. NI K, Zhan Y, Liu Z, Yuan Z, et al
    Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone.
    BMC Cancer. 2023;23:1013.
    PubMed     Abstract available

  70. HOANG T, Cho S, Choi JY, Kang D, et al
    Assessments of dietary intake and polygenic risk score in associations with colorectal cancer risk: evidence from the UK Biobank.
    BMC Cancer. 2023;23:993.
    PubMed     Abstract available

  71. SAJIBU S, Sonder E, Tiwari A, Orjuela S, et al
    Validation of hypermethylated DNA regions found in colorectal cancers as potential aging-independent biomarkers of precancerous colorectal lesions.
    BMC Cancer. 2023;23:998.
    PubMed     Abstract available

  72. BEIHAGHI M, Sahebi R, Beihaghi MR, Nessiani RK, et al
    Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.
    BMC Cancer. 2023;23:985.
    PubMed     Abstract available

  73. LI H, Zhang X, Zhao W, Cai F, et al
    Efficacy of CalliSpheres(R) microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis.
    BMC Cancer. 2023;23:970.
    PubMed     Abstract available

  74. KUOL N, Godlewski J, Kmiec Z, Vogrin S, et al
    Cholinergic signaling influences the expression of immune checkpoint inhibitors, PD-L1 and PD-L2, and tumor hallmarks in human colorectal cancer tissues and cell lines.
    BMC Cancer. 2023;23:971.
    PubMed     Abstract available

  75. CONG J, Gong J, Yang C, Xia Z, et al
    Retraction Note: MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/beta-catenin pathway.
    BMC Cancer. 2023;23:954.

  76. CRESPO-BRAVO M, Thorlacius-Ussing J, Nissen NI, Pedersen RS, et al
    Levels of type XVII collagen (BP180) ectodomain are elevated in circulation from patients with multiple cancer types and is prognostic for patients with metastatic colorectal cancer.
    BMC Cancer. 2023;23:949.
    PubMed     Abstract available

  77. GU J, Deng S, Jiang Z, Mao F, et al
    Modified Naples prognostic score for evaluating the prognosis of patients with obstructive colorectal cancer.
    BMC Cancer. 2023;23:941.
    PubMed     Abstract available

  78. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    PubMed     Abstract available

  79. RAMEZANZADE TABRIZ E, Ramezani M, Heydari A, Aledavood SA, et al
    Development and psychometric properties of Health-Promoting Lifestyle Scale in Colorectal Cancer Survivors (HPLS-CRCS): a mixed-method study.
    BMC Cancer. 2023;23:931.
    PubMed     Abstract available

    September 2023
  80. SHU XP, Xiang YC, Liu F, Cheng Y, et al
    Effect of serum lactate dehydrogenase-to-albumin ratio (LAR) on the short-term outcomes and long-term prognosis of colorectal cancer after radical surgery.
    BMC Cancer. 2023;23:915.
    PubMed     Abstract available

  81. YU YL, Tseng WK, Liao CK, Yeh CY, et al
    Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan.
    BMC Cancer. 2023;23:900.
    PubMed     Abstract available

  82. REN G, Li H, Hong D, Hu F, et al
    LINC00955 suppresses colorectal cancer growth by acting as a molecular scaffold of TRIM25 and Sp1 to Inhibit DNMT3B-mediated methylation of the PHIP promoter.
    BMC Cancer. 2023;23:898.
    PubMed     Abstract available

  83. NING J, Liu M, Shen J, Wang D, et al
    Expression signature and prognostic value of CREC gene family in human colorectal cancer.
    BMC Cancer. 2023;23:878.
    PubMed     Abstract available

  84. LI K, Zhao F, Guo Y, Wu Q, et al
    Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study.
    BMC Cancer. 2023;23:797.
    PubMed     Abstract available

  85. JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
    Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
    BMC Cancer. 2023;23:774.
    PubMed     Abstract available

  86. XIA Q, Cheng W, Bi J, Ren AP, et al
    Value of biplane transrectal ultrasonography plus micro-flow imaging in preoperative T staging and rectal cancer diagnosis in combination with CEA/CA199 and MRI.
    BMC Cancer. 2023;23:860.
    PubMed     Abstract available

  87. SWARTJES H, Qaderi SM, Teerenstra S, Custers JAE, et al
    Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial.
    BMC Cancer. 2023;23:838.
    PubMed     Abstract available

  88. ANDRESEN K, Carreira H, Strongman H, McDonald HI, et al
    The risk of acute kidney injury in colorectal cancer survivors: an english population-based matched cohort study.
    BMC Cancer. 2023;23:839.
    PubMed     Abstract available

    August 2023
  89. FENG Z, Yang X, Tian M, Zeng N, et al
    BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis.
    BMC Cancer. 2023;23:807.
    PubMed     Abstract available

  90. SATGE D, Nishi M, Tretarre B
    Assessing cancer in people with profound and multiple disabilities.
    BMC Cancer. 2023;23:798.
    PubMed     Abstract available

  91. DI Y, Ding L, Gao L, Huang H, et al
    Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:782.
    PubMed     Abstract available

  92. KOBAYASHI S, Bando H, Taketomi A, Takamoto T, et al
    NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligomet
    BMC Cancer. 2023;23:779.
    PubMed     Abstract available

  93. GUO XW, Lei RE, Zhou QN, Zhang G, et al
    Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.
    BMC Cancer. 2023;23:773.
    PubMed     Abstract available

  94. CHEN Q, Cai M, Fan X, Liu W, et al
    An artificial intelligence-based ecological index for prognostic evaluation of colorectal cancer.
    BMC Cancer. 2023;23:763.
    PubMed     Abstract available

  95. FLOUD S, Hermon C, Simpson RF, Reeves GK, et al
    Alcohol consumption and cancer incidence in women: interaction with smoking, body mass index and menopausal hormone therapy.
    BMC Cancer. 2023;23:758.
    PubMed     Abstract available

  96. KIM MJ, Lee DW, Kang HC, Park JW, et al
    Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    BMC Cancer. 2023;23:734.
    PubMed     Abstract available

  97. PUTRI S, Saldi SRF, Khoe LC, Setiawan E, et al
    Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
    BMC Cancer. 2023;23:731.
    PubMed     Abstract available

  98. TAKAHASHI N, Hara H, Nagashima K, Hirata K, et al
    Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
    BMC Cancer. 2023;23:726.
    PubMed     Abstract available

  99. RAOUF M, Sabry AA, Ragab MA, Achy SE, et al
    Detection of Human cytomegalovirus UL55 Gene and IE/E Protein Expression in Colorectal Cancer Patients in Egypt.
    BMC Cancer. 2023;23:723.
    PubMed     Abstract available

  100. AL-OMARI M, Al-Omari T, Batainah N, Al-Qauod K, et al
    Beneficial effects of alpha-1 antitrypsin therapy in a mouse model of colitis-associated colon cancer.
    BMC Cancer. 2023;23:722.
    PubMed     Abstract available

    July 2023
  101. HE Y, He X, Zhou Y, Luo S, et al
    Clinical value of circulating tumor cells and hematological parameters in 617 Chinese patients with colorectal cancer: retrospective analysis.
    BMC Cancer. 2023;23:707.
    PubMed     Abstract available

  102. MITCHELL H, Mclean J, Gavin AT, Visser O, et al
    Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland.
    BMC Cancer. 2023;23:700.
    PubMed     Abstract available

  103. KIM JS, Kim H, Lee SY, Han YD, et al
    Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study - (NCT05103020) - study protocol.
    BMC Cancer. 2023;23:691.
    PubMed     Abstract available

  104. MUNOZ-MONTANO WR, Lopez-Basave HN, Castillo-Morales A, Castillo-Morales C, et al
    Persistent high levels of carcinoembryonic antigen after tumor resection are associated with poorer survival outcomes in patients with resected colon cancer.
    BMC Cancer. 2023;23:678.
    PubMed     Abstract available

  105. FANG X, Zhong C, Weng S, Hu H, et al
    Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
    BMC Cancer. 2023;23:676.
    PubMed     Abstract available

  106. ZHANG B, Lin Y, Wang C, Chen Z, et al
    Combining perineural invasion with staging improve the prognostic accuracy in colorectal cancer: a retrospective cohort study.
    BMC Cancer. 2023;23:675.
    PubMed     Abstract available

  107. XIONG ZZ, Xie MH, Li XZ, Jin LY, et al
    Risk factors for postoperative recurrence in patients with stage II colorectal cancer.
    BMC Cancer. 2023;23:658.
    PubMed     Abstract available

  108. LAMMINMAKI M, Leivonen A, Heinavaara S, Nygard M, et al
    A population-based cohort study on changes in breast, lung and colorectal cancer incidence and mortality among non-Western immigrant women.
    BMC Cancer. 2023;23:665.
    PubMed     Abstract available

  109. BJORNETRO T, Bousquet PA, Redalen KR, Troseid AS, et al
    Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients.
    BMC Cancer. 2023;23:650.
    PubMed     Abstract available

  110. KOLISNIK T, Sulit AK, Schmeier S, Frizelle F, et al
    Identifying important microbial and genomic biomarkers for differentiating right- versus left-sided colorectal cancer using random forest models.
    BMC Cancer. 2023;23:647.
    PubMed     Abstract available

  111. WOO HT, Jeong SY, Shin A
    The association between prescription drugs and colorectal cancer prognosis: a nationwide cohort study using a medication-wide association study.
    BMC Cancer. 2023;23:643.
    PubMed     Abstract available

  112. LI Q, An T, Wu J, Lu W, et al
    The impact of sarcopenia on the outcome of patients with left-sided colon and rectal cancer after curative surgery.
    BMC Cancer. 2023;23:640.
    PubMed     Abstract available

  113. FUKUDA K, Osumi H, Yoshino K, Nakayama I, et al
    Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
    BMC Cancer. 2023;23:634.
    PubMed     Abstract available

  114. SADEGHI A, Asadzadeh Aghdaei H, Khalafi MA, Nazemalhosseini-Mojarad E, et al
    The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study.
    BMC Cancer. 2023;23:627.
    PubMed     Abstract available

  115. YE Z, Song G, Liang J, Yi S, et al
    Optimized screening of DNA methylation sites combined with gene expression analysis to identify diagnostic markers of colorectal cancer.
    BMC Cancer. 2023;23:617.
    PubMed     Abstract available

  116. FU J, Du F, Tian T, Huang H, et al
    Development and validation of prognostic nomograms based on De Ritis ratio and clinicopathological features for patients with stage II/III colorectal cancer.
    BMC Cancer. 2023;23:620.
    PubMed     Abstract available

  117. LI Y, Lou J, Hong S, Hou D, et al
    The role of heavy metals in the development of colorectal cancer.
    BMC Cancer. 2023;23:616.
    PubMed     Abstract available

    June 2023
  118. XIANG M, Gao Y, Zhou Y, Wang M, et al
    A novel nomogram based on cell cycle-related genes for predicting overall survival in early-onset colorectal cancer.
    BMC Cancer. 2023;23:595.
    PubMed     Abstract available

  119. ZHANG W, Zhou H, Jiang J, Zhu Y, et al
    Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    BMC Cancer. 2023;23:592.
    PubMed     Abstract available

  120. MA B, Wang X, Ren H, Li Y, et al
    High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist.
    BMC Cancer. 2023;23:594.
    PubMed     Abstract available

  121. ZHOU CJ, Lin Y, Liu JY, Wang ZL, et al
    Malnutrition and visceral obesity predicted adverse short-term and long-term outcomes in patients undergoing proctectomy for rectal cancer.
    BMC Cancer. 2023;23:576.
    PubMed     Abstract available

  122. LEE WA, Chung WP, Shao SC, Lai EC, et al
    Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors - a population-based cohort study.
    BMC Cancer. 2023;23:545.
    PubMed     Abstract available

  123. HABR-GAMA A, Sao Juliao GP, Ortega CD, Vailati BB, et al
    A multi-centre randomized controlled trial investigating Consolidation Chemotherapy with and without oxaliplatin in distal rectal cancer and Watch & Wait.
    BMC Cancer. 2023;23:546.
    PubMed     Abstract available

  124. QIAO Y, Li X, Hu Y, Guo P, et al
    Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation.
    BMC Cancer. 2023;23:535.
    PubMed     Abstract available

  125. MOSLEHIAN MS, Shabkhizan R, Asadi MR, Bazmani A, et al
    Interaction of lncRNAs with mTOR in colorectal cancer: a systematic review.
    BMC Cancer. 2023;23:512.
    PubMed     Abstract available

  126. TONG S, Li M, Bao Y, Zhang L, et al
    Size and number of lymph nodes were risk factors of recurrence in stage II colorectal cancer.
    BMC Cancer. 2023;23:518.
    PubMed     Abstract available

    May 2023
  127. MURAKAWA Y, Ootsuka K, Kusaka J, Miura K, et al
    Correlation between overall survival and quality of life in colon cancer patients with chemotherapy.
    BMC Cancer. 2023;23:492.
    PubMed     Abstract available

  128. YANG H, Huebner K, Hampel C, Erlenbach-Wuensch K, et al
    ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
    BMC Cancer. 2023;23:480.
    PubMed     Abstract available

  129. KANAI R, Uehara T, Yoshizawa T, Kamakura M, et al
    ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer.
    BMC Cancer. 2023;23:478.
    PubMed     Abstract available

  130. LEONG E, Ong SK, Si-Ramlee KA, Naing L, et al
    Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020.
    BMC Cancer. 2023;23:466.
    PubMed     Abstract available

  131. SHI J, Cheng YK, He F, Zheng J, et al
    Effects of neoadjuvant radiochemotherapy for anorectal function in locally advanced rectal cancer patients: a study protocol for a prospective, observational, controlled, multicentre study.
    BMC Cancer. 2023;23:467.
    PubMed     Abstract available

  132. KEHMANN L, Berres ML, Gonzalez-Carmona M, Modest DP, et al
    Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
    BMC Cancer. 2023;23:470.
    PubMed     Abstract available

  133. QIN L, Heng Y, Deng S, Gu J, et al
    Perineural invasion affects prognosis of patients undergoing colorectal cancer surgery: a propensity score matching analysis.
    BMC Cancer. 2023;23:452.
    PubMed     Abstract available

  134. ABE S, Kawai K, Nozawa H, Sasaki K, et al
    Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
    BMC Cancer. 2023;23:450.
    PubMed     Abstract available

  135. HUANG C, Wang L, Chen H, Fu W, et al
    A positive feedback loop between ID3 and PPARgamma via DNA damage repair regulates the efficacy of radiotherapy for rectal cancer.
    BMC Cancer. 2023;23:429.
    PubMed     Abstract available

  136. YANG Y, Lu Y, Tan H, Bai M, et al
    The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer.
    BMC Cancer. 2023;23:422.
    PubMed     Abstract available

  137. DEEN R, Ediriweera DS, Thillakaratne S, Hewavissenthi J, et al
    Neoadjuvant Chemoradiation for Rectal Cancer Achieves Satisfactory Tumour Regression and Local Recurrence - Result of a Dedicated Multi-disciplinary Approach from a South Asian Centre.
    BMC Cancer. 2023;23:400.
    PubMed     Abstract available

  138. AHMED AM, Bacchus MW, Beal SG, Huber KN, et al
    Colorectal cancer screening completion by patients due or overdue for screening after reminders: a retrospective study.
    BMC Cancer. 2023;23:391.
    PubMed     Abstract available

    April 2023
  139. PENG J, Wang W, Jin H, Qin X, et al
    Develop and validate a radiomics space-time model to predict the pathological complete response in patients undergoing neoadjuvant treatment of rectal cancer: an artificial intelligence model study based on machine learning.
    BMC Cancer. 2023;23:365.
    PubMed     Abstract available

  140. ARASAWA T, Hiwasa T, Kagaya A, Maruyama T, et al
    Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels.
    BMC Cancer. 2023;23:356.
    PubMed     Abstract available

  141. KAHRIZSANGI MA, Ebrahimi Z, Shateri Z, Mansouri F, et al
    Carbohydrate quality indices and colorectal cancer risk: a case-control study.
    BMC Cancer. 2023;23:347.
    PubMed     Abstract available

  142. YU J, Sun Q, Hui Y, Xu J, et al
    Vitamin D receptor prevents tumour development by regulating the Wnt/beta-catenin signalling pathway in human colorectal cancer.
    BMC Cancer. 2023;23:336.
    PubMed     Abstract available

  143. SHANG K, Ma N, Che J, Li H, et al
    SLC27A2 mediates FAO in colorectal cancer through nongenic crosstalk regulation of the PPARs pathway.
    BMC Cancer. 2023;23:335.
    PubMed     Abstract available

  144. DAI W, Guo C, Wang Y, Li Y, et al
    Identification of hub genes and pathways in lung metastatic colorectal cancer.
    BMC Cancer. 2023;23:323.
    PubMed     Abstract available

  145. LI X, Cai D, Huang Y, Xie Y, et al
    Aberrant methylation in neurofunctional gene serves as a hallmark of tumorigenesis and progression in colorectal cancer.
    BMC Cancer. 2023;23:315.
    PubMed     Abstract available

  146. KIM I, Lim JY, Kim SW, Shin DW, et al
    Effectiveness of personalized treatment stage-adjusted digital therapeutics in colorectal cancer: a randomized controlled trial.
    BMC Cancer. 2023;23:304.
    PubMed     Abstract available

  147. HIMBERT C, Ose J, Gigic B, Viskochil R, et al
    Associations of combined physical activity and body mass index groups with colorectal cancer survival outcomes.
    BMC Cancer. 2023;23:300.
    PubMed     Abstract available

    March 2023
  148. LINKE C, Hunger R, Reinwald M, Deckert M, et al
    Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.
    BMC Cancer. 2023;23:291.
    PubMed     Abstract available

  149. WANG SY, Zhang WS, Jiang CQ, Jin YL, et al
    Association of novel and conventional obesity indices with colorectal cancer risk in older Chinese: a 14-year follow-up of the Guangzhou Biobank Cohort Study.
    BMC Cancer. 2023;23:286.
    PubMed     Abstract available

  150. HAN J, Liu X, Tang M, Yang F, et al
    Abdominal fat and muscle distributions in different stages of colorectal cancer.
    BMC Cancer. 2023;23:279.
    PubMed     Abstract available

  151. SLATER S, Bryant A, Chen HC, Begum R, et al
    ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
    BMC Cancer. 2023;23:257.
    PubMed     Abstract available

  152. HUANG X, Zheng Z, Zeng B, Xiao H, et al
    Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study.
    BMC Cancer. 2023;23:238.
    PubMed     Abstract available

  153. BOGNER A, Weitz J, Piontek D
    The influence of socioeconomic aspects and hospital case volume on survival in colorectal cancer in Saxony, Germany.
    BMC Cancer. 2023;23:228.
    PubMed     Abstract available

  154. YANG L, Liu S, He W, Xiong Z, et al
    Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
    BMC Cancer. 2023;23:221.
    PubMed     Abstract available

  155. ZHANG KH, Li JZ, Zhang HB, Hu RH, et al
    Assessment of Autologous Blood marker localIzation and intraoperative coLonoscopy localIzation in laparoscopic colorecTal cancer surgery (ABILITY): a randomized controlled trial.
    BMC Cancer. 2023;23:204.
    PubMed     Abstract available

  156. DENG S, Zhu Q, Chen H, Xiao T, et al
    Screening of prognosis-related Immune cells and prognostic predictors in Colorectal Cancer Patients.
    BMC Cancer. 2023;23:195.
    PubMed     Abstract available

    February 2023
  157. MENG Q, Zhao J, Yu Y, Wang K, et al
    Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
    BMC Cancer. 2023;23:191.
    PubMed     Abstract available

  158. JUNAID F, Tomic G, Kemp R, Winton DJ, et al
    Single-copy Snail upregulation causes partial epithelial-mesenchymal transition in colon cancer cells.
    BMC Cancer. 2023;23:153.
    PubMed     Abstract available

  159. VOLKEL V, Steinger B, Koller M, Klinkhammer-Schalke M, et al
    Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial.
    BMC Cancer. 2023;23:149.
    PubMed     Abstract available

  160. ZHANG Y, Zhang H, Zhu J, He Y, et al
    Association between diverticular disease and colorectal cancer: a bidirectional mendelian randomization study.
    BMC Cancer. 2023;23:137.
    PubMed     Abstract available

  161. ABDUL RAHMAN H, Ottom MA, Dinov ID
    Machine learning-based colorectal cancer prediction using global dietary data.
    BMC Cancer. 2023;23:144.
    PubMed     Abstract available

  162. XU Y, Zhu Y, Xia H, Wang Y, et al
    Tumor necrosis factor-alpha-inducible protein 8-like protein 3 (TIPE3): a novel prognostic factor in colorectal cancer.
    BMC Cancer. 2023;23:131.
    PubMed     Abstract available

  163. ZHANG H, Lin F, Wang Z
    Mean platelet volume/platelet count ratio in combination with tumor markers in colorectal cancer: a retrospective clinical study.
    BMC Cancer. 2023;23:124.
    PubMed     Abstract available

    January 2023
  164. ZHANG H, Wang C, Liu Y, Hu H, et al
    The optimal minimum lymph node count for carcinoembryonic antigen elevated colon cancer: a population-based study in the SEER set and External set.
    BMC Cancer. 2023;23:100.
    PubMed     Abstract available

  165. TAIEB J, Price T, Vidot L, Chevallier B, et al
    Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
    BMC Cancer. 2023;23:94.
    PubMed     Abstract available

  166. MORISHIMA T, Kuwabara Y, Saito MK, Odani S, et al
    Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: a Japanese multicentre cohort study.
    BMC Cancer. 2023;23:67.
    PubMed     Abstract available

  167. NOZAWA H, Taira T, Sonoda H, Sasaki K, et al
    Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms.
    BMC Cancer. 2023;23:62.
    PubMed     Abstract available

  168. TONG P, Sun D, Chen G, Ni J, et al
    Biparametric magnetic resonance imaging-based radiomics features for prediction of lymphovascular invasion in rectal cancer.
    BMC Cancer. 2023;23:61.
    PubMed     Abstract available

  169. YAP S, He E, Egger S, Goldsbury DE, et al
    Colon and rectal cancer treatment patterns and their associations with clinical, sociodemographic and lifestyle characteristics: analysis of the Australian 45 and Up Study cohort.
    BMC Cancer. 2023;23:60.
    PubMed     Abstract available

  170. ARAYNE AA, Gartrell R, Qiao J, Baird PN, et al
    Comparison of CT derived body composition at the thoracic T4 and T12 with lumbar L3 vertebral levels and their utility in patients with rectal cancer.
    BMC Cancer. 2023;23:56.
    PubMed     Abstract available

  171. HUANG K, Luo W, Fang J, Yu C, et al
    Notch3 signaling promotes colorectal tumor growth by enhancing immunosuppressive cells infiltration in the microenvironment.
    BMC Cancer. 2023;23:55.
    PubMed     Abstract available

  172. WANG B, Zhang J, Wang X, Zhao L, et al
    Identification and clinical validation of key genes as the potential biomarkers in colorectal adenoma.
    BMC Cancer. 2023;23:39.
    PubMed     Abstract available

  173. SCHLIEMANN D, Ramanathan K, Ibrahim Tamin NSB, O'Neill C, et al
    Implementation of a home-based colorectal cancer screening intervention in Malaysia (CRC-SIM).
    BMC Cancer. 2023;23:22.
    PubMed     Abstract available

  174. BOURMAUD A, Benoist Y, Tinquaut F, Allary C, et al
    Patient navigation for colorectal cancer screening in deprived areas: the COLONAV cluster randomized controlled trial.
    BMC Cancer. 2023;23:21.
    PubMed     Abstract available

  175. GUITTET L, Quipourt V, Aparicio T, Carola E, et al
    Should we screen for colorectal cancer in people aged 75 and over? A systematic review - collaborative work of the French geriatric oncology society (SOFOG) and the French federation of digestive oncology (FFCD).
    BMC Cancer. 2023;23:17.
    PubMed     Abstract available

  176. ZHANG L, Deng Y, Liu S, Zhang W, et al
    Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients.
    BMC Cancer. 2023;23:3.
    PubMed     Abstract available

  177. RUBIO-MANGAS D, Garcia-Arranz M, Torres-Rodriguez Y, Leon-Arellano M, et al
    Differential presence of exons (DPE): sequencing liquid biopsy by NGS. A new method for clustering colorectal Cancer patients.
    BMC Cancer. 2023;23:2.
    PubMed     Abstract available

  178. PENG BY, Singh AK, Chan CH, Deng YH, et al
    AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway.
    BMC Cancer. 2023;23:1.
    PubMed     Abstract available

    December 2022
  179. NI JJ, Li XS, Zhang H, Xu Q, et al
    Mendelian randomization study of causal link from gut microbiota to colorectal cancer.
    BMC Cancer. 2022;22:1371.
    PubMed     Abstract available

  180. LIU X, Wu B, Chen H, Sun H, et al
    Intense endoplasmic reticulum stress (ERS) / IRE1alpha enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells.
    BMC Cancer. 2022;22:1369.
    PubMed     Abstract available

  181. CUI Z, Du L, Wang J, Li Z, et al
    Overexpression of CENPL mRNA potentially regulated by miR-340-3p predicts the prognosis of pancreatic cancer patients.
    BMC Cancer. 2022;22:1354.
    PubMed     Abstract available

  182. XIE H, Wei L, Liu M, Liang Y, et al
    Prognostic significance of preoperative prognostic immune and nutritional index in patients with stage I-III colorectal cancer.
    BMC Cancer. 2022;22:1316.
    PubMed     Abstract available

  183. ERIKSEN M, Pfeiffer P, Rohrberg KS, Yde CW, et al
    A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
    BMC Cancer. 2022;22:1321.
    PubMed     Abstract available

  184. WANG Y, Zheng R, Zhang Y, Guo Y, et al
    Galectin-9 expression clinically associated with mature dendritic cells infiltration and T cell immune response in colorectal cancer.
    BMC Cancer. 2022;22:1319.
    PubMed     Abstract available

  185. FIDELMAN N, Atreya CE, Griffith M, Milloy MA, et al
    Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases.
    BMC Cancer. 2022;22:1307.
    PubMed     Abstract available

  186. TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
    Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
    BMC Cancer. 2022;22:1303.
    PubMed     Abstract available

  187. WISSE PHA, de Klaver W, van Wifferen F, Meiqari L, et al
    The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    BMC Cancer. 2022;22:1299.
    PubMed     Abstract available

  188. DOMBEK GE, Ore AS, Cheng J, Matsumoto Y, et al
    Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions.
    BMC Cancer. 2022;22:1281.
    PubMed     Abstract available

  189. TAKASU C, Nishi M, Yoshikawa K, Tokunaga T, et al
    Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    BMC Cancer. 2022;22:1263.
    PubMed     Abstract available

    November 2022
  190. SONG M, Wang H, Wang L, Li S, et al
    Dentate line invasion as a predictive factor of poor distant relapse-free survival in locally advanced lower rectal cancer with anal sphincter involvement.
    BMC Cancer. 2022;22:1196.
    PubMed     Abstract available

  191. ZHANG C, Zhan Y, Ni K, Liu Z, et al
    Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
    BMC Cancer. 2022;22:1156.
    PubMed     Abstract available

  192. CHENG X, Shen T, Liu P, Fang S, et al
    mir-145-5p is a suppressor of colorectal cancer at early stage, while promotes colorectal cancer metastasis at late stage through regulating AKT signaling evoked EMT-mediated anoikis.
    BMC Cancer. 2022;22:1151.
    PubMed     Abstract available

  193. JAFARI M, Laraqui A, Baba W, Benmokhtar S, et al
    Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
    BMC Cancer. 2022;22:1142.
    PubMed     Abstract available

  194. LINCOLN A, Benton S, Piggott C, North BV, et al
    Exploring the utility and acceptability of Faecal immunochemical testing (FIT) as a novel intervention for the improvement of colorectal Cancer (CRC) surveillance in individuals with lynch syndrome (FIT for lynch study): a single-arm, prospective, mul
    BMC Cancer. 2022;22:1144.
    PubMed     Abstract available

  195. LIU S, Wang YL, Shi ST, Zeng GD, et al
    The effect of recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study.
    BMC Cancer. 2022;22:1140.
    PubMed     Abstract available

  196. BREADNER D, Loree JM, Cheung WY, Gipson M, et al
    The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis.
    BMC Cancer. 2022;22:1119.
    PubMed     Abstract available

    October 2022
  197. SOROKIN M, Zolotovskaia M, Nikitin D, Suntsova M, et al
    Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.
    BMC Cancer. 2022;22:1113.
    PubMed     Abstract available

  198. DAVIS SL, Hartman SJ, Bagby SM, Schlaepfer M, et al
    ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
    BMC Cancer. 2022;22:1107.
    PubMed     Abstract available

  199. ZHANG W, Han X, Yang L, Song Y, et al
    Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.
    BMC Cancer. 2022;22:1104.
    PubMed     Abstract available

  200. CHEN Y, Li Y, Mo S, Hu X, et al
    The pattern and treatment outcomes for rectal cancer with concurrent locoregional recurrence and distant metastases after total mesorectal excision.
    BMC Cancer. 2022;22:1088.
    PubMed     Abstract available

  201. MCCABE M, Penny C, Magangane P, Mirza S, et al
    Left-sided colorectal cancer distinct in indigenous African patients compared to other ethnic groups in South Africa.
    BMC Cancer. 2022;22:1089.
    PubMed     Abstract available

  202. NAKAGAMI Y, Hazama S, Suzuki N, Yoshida S, et al
    CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule.
    BMC Cancer. 2022;22:1071.
    PubMed     Abstract available

  203. VEENSTRA CM, Ellis KR, Abrahamse P, Ward KC, et al
    A dyadic survey study of partner engagement in and patient receipt of guideline-recommended colorectal cancer surveillance.
    BMC Cancer. 2022;22:1060.
    PubMed     Abstract available

  204. YAN X, Hong B, Feng J, Jin Y, et al
    B7-H4 is a potential diagnostic and prognostic biomarker in colorectal cancer and correlates with the epithelial-mesenchymal transition.
    BMC Cancer. 2022;22:1053.
    PubMed     Abstract available

  205. WANG S, Yuan Z, Wang Y, Zhao X, et al
    Modifiable lifestyle factors have a larger contribution to colorectal neoplasms than family history.
    BMC Cancer. 2022;22:1051.
    PubMed     Abstract available

  206. ZHANG S, Pan G, Liu Z, Kong Y, et al
    Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study.
    BMC Cancer. 2022;22:1043.
    PubMed     Abstract available

  207. LIU J, Li Y, Xiao Q, Li Y, et al
    Identification of CPT2 as a prognostic biomarker by integrating the metabolism-associated gene signature in colorectal cancer.
    BMC Cancer. 2022;22:1038.
    PubMed     Abstract available

    September 2022
  208. LIU T, Zhang Q, Wang Y, Ma X, et al
    Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer.
    BMC Cancer. 2022;22:1007.
    PubMed     Abstract available

  209. XIANG J, Gao L, Jing HY, Liu YX, et al
    Construction of CeRNA regulatory network based on WGCNA reveals diagnosis biomarkers for colorectal cancer.
    BMC Cancer. 2022;22:991.
    PubMed     Abstract available

  210. NOTI L, Galvan JA, Dawson H, Lugli A, et al
    A combined spatial score of granzyme B and CD68 surpasses CD8 as an independent prognostic factor in TNM stage II colorectal cancer.
    BMC Cancer. 2022;22:987.
    PubMed     Abstract available

  211. FENG WM, Gong H, Wang YC, Wang Y, et al
    NudCD1 as a prognostic marker in colorectal cancer and its role in the upregulation of cellular spindle assembly checkpoint genes and LIS1 pathways.
    BMC Cancer. 2022;22:981.
    PubMed     Abstract available

  212. CHERAGHI O, Dabirmanesh B, Ghazi F, Amanlou M, et al
    The effect of Nrf2 deletion on the proteomic signature in a human colorectal cancer cell line.
    BMC Cancer. 2022;22:979.
    PubMed     Abstract available

  213. HOYDAHL O, Edna TH, Xanthoulis A, Lydersen S, et al
    The impact of age on rectal cancer treatment, complications and survival.
    BMC Cancer. 2022;22:975.
    PubMed     Abstract available

  214. LI Z, Zhu H, Pang X, Mao Y, et al
    Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
    BMC Cancer. 2022;22:962.
    PubMed     Abstract available

  215. KONG Y, Zhuo L, Dong D, Zhuo L, et al
    Validation of the Asia-Pacific colorectal screening score and its modified versions in predicting colorectal advanced neoplasia in Chinese population.
    BMC Cancer. 2022;22:961.
    PubMed     Abstract available

  216. VAN DEN BERG K, Schaap DP, Voogt ELK, Buffart TE, et al
    Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    BMC Cancer. 2022;22:957.
    PubMed     Abstract available

    August 2022
  217. KIM KM, Ahn AR, Park HS, Jang KY, et al
    Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    BMC Cancer. 2022;22:940.
    PubMed     Abstract available

  218. WANG F, Huang C, Long J, Zhao ZB, et al
    Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer.
    BMC Cancer. 2022;22:933.
    PubMed     Abstract available

  219. LI X, Lan Q, Lai W, Wu H, et al
    Exosome-derived lnc-HOXB8-1:2 induces tumor-associated macrophage infiltration to promote neuroendocrine differentiated colorectal cancer progression by sponging hsa-miR-6825-5p.
    BMC Cancer. 2022;22:928.
    PubMed     Abstract available

  220. CHEN Q, Li M, Chen J, Huang Z, et al
    AST.MLR index and operation injury condition are novel prognostic predictor for the prediction of survival in patients with colorectal cancer liver metastases undergoing surgical resection.
    BMC Cancer. 2022;22:921.
    PubMed     Abstract available

  221. WANG C, Wang B, Liang W, Zhou C, et al
    Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10.
    BMC Cancer. 2022;22:922.
    PubMed     Abstract available

  222. DING X, Sun D, Guo Q, Li Y, et al
    The value of diffusion kurtosis imaging and intravoxel incoherent motion quantitative parameters in predicting synchronous distant metastasis of rectal cancer.
    BMC Cancer. 2022;22:920.
    PubMed     Abstract available

  223. SUN S, Sun S, Zheng X, Yu J, et al
    Long-term outcomes of laparoscopic Extralevator Abdominoperineal excision with modified position change for low rectal Cancer treatment.
    BMC Cancer. 2022;22:916.
    PubMed     Abstract available

  224. ESTEVA M, Leiva A, Ramos-Monserrat M, Espi A, et al
    Relationship between time from symptom's onset to diagnosis and prognosis in patients with symptomatic colorectal cancer.
    BMC Cancer. 2022;22:910.
    PubMed     Abstract available

  225. HOPPENER DJ, Stook JPL, Galjart B, Nierop PMH, et al
    The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases.
    BMC Cancer. 2022;22:911.
    PubMed     Abstract available

  226. LJUNGGREN M, Weibull CE, Rosander E, Palmer G, et al
    Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study.
    BMC Cancer. 2022;22:907.
    PubMed     Abstract available

  227. ZHENG G, Sundquist J, Sundquist K, Ji J, et al
    Colorectal cancer risk in association with colorectal cancer as a second malignancy in relatives: a nationwide cohort study.
    BMC Cancer. 2022;22:902.
    PubMed     Abstract available

  228. ZHAO Z, Liu H, Fang D, Zhou X, et al
    Patient stratification based on urea cycle metabolism for exploration of combination immunotherapy in colon cancer.
    BMC Cancer. 2022;22:883.
    PubMed     Abstract available

  229. WANG H, Ji D, Tian H, Gao Z, et al
    Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy.
    BMC Cancer. 2022;22:868.
    PubMed     Abstract available

  230. KIM JK, Rhee YY, Bae JM, Kim JH, et al
    Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer.
    BMC Cancer. 2022;22:861.
    PubMed     Abstract available

  231. ZHANG Z, Zhang Y, Lao S, Qiu J, et al
    The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer.
    BMC Cancer. 2022;22:855.
    PubMed     Abstract available

  232. ZHANG B, Liu XY, Kang B, Yuan C, et al
    Preoperative hypokalemia can increase complications after colorectal cancer surgery: a propensity score matching analysis.
    BMC Cancer. 2022;22:846.
    PubMed     Abstract available

  233. KANNO H, Hisaka T, Akiba J, Hashimoto K, et al
    C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of Foxp3+ or CD3+ lymphocytes in colorectal liver metastasis.
    BMC Cancer. 2022;22:839.
    PubMed     Abstract available

    July 2022
  234. LU Y, Jiang Z, Wang K, Yu S, et al
    Blockade of the amino acid transporter SLC6A14 suppresses tumor growth in colorectal Cancer.
    BMC Cancer. 2022;22:833.
    PubMed     Abstract available

  235. SAMADI P, Soleimani M, Nouri F, Rahbarizadeh F, et al
    An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer.
    BMC Cancer. 2022;22:835.
    PubMed     Abstract available

  236. ZHANG X, Yuan JR, Wang X, Fu S, et al
    Association between c-type lectin-like receptor 2 and microsatellite instability in colorectal cancer: a cross-sectional study.
    BMC Cancer. 2022;22:823.
    PubMed     Abstract available

  237. SOMMERHAUSER G, Kurreck A, Stintzing S, Heinemann V, et al
    Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line
    BMC Cancer. 2022;22:820.
    PubMed     Abstract available

  238. WANG C, Aikemu B, Shao Y, Zhang S, et al
    Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer.
    BMC Cancer. 2022;22:818.
    PubMed     Abstract available

  239. ZEMAN M, Skalba W, Wilk AM, Cortez AJ, et al
    Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer.
    BMC Cancer. 2022;22:815.
    PubMed     Abstract available

  240. SONG J, Li Z, Yang L, Wei M, et al
    Metabolic activity via (18)F-FDG PET/CT is predictive of microsatellite instability status in colorectal cancer.
    BMC Cancer. 2022;22:808.
    PubMed     Abstract available

  241. LIU X, Ou K, Ma X, Gao L, et al
    Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    BMC Cancer. 2022;22:807.
    PubMed     Abstract available

  242. ZHANG J, Deng J, Hu J, Zhong Q, et al
    Safety and feasibility of neoadjuvant chemotherapy as a surgical bridge for acute left-sided malignant colorectal obstruction: a retrospective study.
    BMC Cancer. 2022;22:806.
    PubMed     Abstract available

  243. LI A, Huang T, Zheng R, Chi P, et al
    Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.
    BMC Cancer. 2022;22:789.
    PubMed     Abstract available

  244. LI M, Guo D, Chen X, Lu X, et al
    Transcriptome profiling and co-expression network analysis of lncRNAs and mRNAs in colorectal cancer by RNA sequencing.
    BMC Cancer. 2022;22:780.
    PubMed     Abstract available

  245. CORRO C, Buchs NC, Tihy M, Durham-Faivre A, et al
    Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer.
    BMC Cancer. 2022;22:772.
    PubMed     Abstract available

  246. SONG Z, Liu K, Zhang T, Wang B, et al
    Oncologic outcomes of single-incision laparoscopic surgery versus conventional laparoscopic surgery for colorectal cancer (CSILS): study protocol for a multicentre, prospective, open-label, noninferiority, randomized controlled trial.
    BMC Cancer. 2022;22:743.
    PubMed     Abstract available

  247. ZAINAL ABIDIN MN, Omar MS, Islahudin F, Mohamed Shah N, et al
    The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer.
    BMC Cancer. 2022;22:731.
    PubMed     Abstract available

    June 2022
  248. OOKI A, Morita S, Tsuji A, Iwamoto S, et al
    Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.
    BMC Cancer. 2022;22:711.
    PubMed     Abstract available

  249. NIMPTSCH K, Aleksandrova K, Fedirko V, Jenab M, et al
    Pre-diagnostic C-reactive protein concentrations, CRP genetic variation and mortality among individuals with colorectal cancer in Western European populations.
    BMC Cancer. 2022;22:695.
    PubMed     Abstract available

  250. PRINCIPE DR, Cataneo JL, Timbers KE, Koch RM, et al
    Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma.
    BMC Cancer. 2022;22:697.
    PubMed     Abstract available

  251. CHEN Y, Xu M, Ye Q, Xiang J, et al
    Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer.
    BMC Cancer. 2022;22:670.
    PubMed     Abstract available

  252. GUADAGNI S, Masedu F, Fiorentini G, Sarti D, et al
    Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver
    BMC Cancer. 2022;22:660.
    PubMed     Abstract available

  253. HOANG T, Kim MJ, Park JW, Jeong SY, et al
    Nutrition-wide association study of microbiome diversity and composition in colorectal cancer patients.
    BMC Cancer. 2022;22:656.
    PubMed     Abstract available

  254. ZHENG R, Zhang Y, Chen R, Guan B, et al
    Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement.
    BMC Cancer. 2022;22:657.
    PubMed     Abstract available

  255. DENG S, Jiang Z, Cao Y, Gu J, et al
    Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study.
    BMC Cancer. 2022;22:643.
    PubMed     Abstract available

  256. THEOPHANOUS S, Samuel R, Lilley J, Henry A, et al
    Prognostic factors for patients with anal cancer treated with conformal radiotherapy-a systematic review.
    BMC Cancer. 2022;22:607.
    PubMed     Abstract available

  257. SU W, Feng B, Hu L, Guo X, et al
    MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway.
    BMC Cancer. 2022;22:602.
    PubMed     Abstract available

  258. AL-MTERIN MA, Murshed K, Alsalman A, Abu-Dayeh A, et al
    Associations of different immune checkpoints-expressing CD4(+) Treg/ T cell subsets with disease-free survival in colorectal cancer patients.
    BMC Cancer. 2022;22:601.
    PubMed     Abstract available

  259. SZIGETI KA, Kalmar A, Galamb O, Valcz G, et al
    Global DNA hypomethylation of colorectal tumours detected in tissue and liquid biopsies may be related to decreased methyl-donor content.
    BMC Cancer. 2022;22:605.
    PubMed     Abstract available

  260. LIU XY, Kang B, Cheng YX, Yuan C, et al
    Higher body mass index was associated with better prognosis in diabetic patients with stage II colorectal cancer.
    BMC Cancer. 2022;22:596.
    PubMed     Abstract available

    May 2022
  261. PAUL M, Gope TK, Das P, Ain R, et al
    Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression.
    BMC Cancer. 2022;22:594.
    PubMed     Abstract available

  262. LU Y, Gehr AW, Meadows RJ, Ghabach B, et al
    Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system.
    BMC Cancer. 2022;22:593.
    PubMed     Abstract available

  263. SHEN MH, Huang CJ, Ho TF, Liu CY, et al
    Colorectal cancer concurrent gene signature based on coherent patterns between genomic and transcriptional alterations.
    BMC Cancer. 2022;22:590.
    PubMed     Abstract available

  264. BUGGISCH JR, Gohler D, Sobilo J, Lerondel S, et al
    Development and technical validation of an ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer peritoneal metastases model.
    BMC Cancer. 2022;22:570.
    PubMed     Abstract available

  265. ZICHITTELLA C, Barreca MM, Cordaro A, Corrado C, et al
    Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells.
    BMC Cancer. 2022;22:567.
    PubMed     Abstract available

  266. ZHANG M, Peng Y, Yang Z, Zhang H, et al
    DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer.
    BMC Cancer. 2022;22:561.
    PubMed     Abstract available

  267. KOHLS M, Freisling H, Charvat H, Soerjomataram I, et al
    Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
    BMC Cancer. 2022;22:546.
    PubMed     Abstract available

  268. PEREIRA F, Serrano A, Manzanedo I, Perez-Viejo E, et al
    GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
    BMC Cancer. 2022;22:536.
    PubMed     Abstract available

  269. YING M, Pan J, Lu G, Zhou S, et al
    Development and validation of a radiomics-based nomogram for the preoperative prediction of microsatellite instability in colorectal cancer.
    BMC Cancer. 2022;22:524.
    PubMed     Abstract available

  270. LINDENBERG M, Kramer A, Kok E, Retel V, et al
    Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness.
    BMC Cancer. 2022;22:504.
    PubMed     Abstract available

  271. ABE S, Kawai K, Nozawa H, Sasaki K, et al
    Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.
    BMC Cancer. 2022;22:486.
    PubMed     Abstract available

  272. YANG Y, Ye F, Xia T, Wang Q, et al
    High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
    BMC Cancer. 2022;22:487.
    PubMed     Abstract available

    April 2022
  273. YANG Z, Zhang X, Zhang J, Gao J, et al
    Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT
    BMC Cancer. 2022;22:462.
    PubMed     Abstract available

  274. XU L, He H, Shang Y, Qu X, et al
    LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression.
    BMC Cancer. 2022;22:453.
    PubMed     Abstract available

  275. BAHRAMI M, Masoumy M, Sadeghi A, Mosavizadeh R, et al
    Development, implementation and evaluation a palliative care program for colorectal cancer patients: a mixed methods protocol study.
    BMC Cancer. 2022;22:441.
    PubMed     Abstract available

  276. BHUROSY T, Jishan A, Boland PM, Lee YH, et al
    Underdiagnosis of iron deficiency anemia among patients with colorectal cancer: an examination of electronic medical records.
    BMC Cancer. 2022;22:435.
    PubMed     Abstract available

  277. RAHIMINEJAD S, Maurya MR, Mukund K, Subramaniam S, et al
    Modular and mechanistic changes across stages of colorectal cancer.
    BMC Cancer. 2022;22:436.
    PubMed     Abstract available

  278. ARAI J, Otoyama Y, Fujita KI, Goto K, et al
    Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
    BMC Cancer. 2022;22:428.
    PubMed     Abstract available

  279. LIU Y, Kong XX, He JJ, Xu YB, et al
    OLA1 promotes colorectal cancer tumorigenesis by activation of HIF1alpha/CA9 axis.
    BMC Cancer. 2022;22:424.
    PubMed     Abstract available

  280. WANG J, Chen J, Zhou R, Gao Y, et al
    Machine learning-based multiparametric MRI radiomics for predicting poor responders after neoadjuvant chemoradiotherapy in rectal Cancer patients.
    BMC Cancer. 2022;22:420.
    PubMed     Abstract available

  281. TEN HOORN S, Waasdorp C, van Oijen MGH, Damhofer H, et al
    Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer.
    BMC Cancer. 2022;22:394.
    PubMed     Abstract available

  282. YAGYU T, Yamamoto M, Tanio A, Hara K, et al
    Risk factors for recurrence in elderly patients with stage II colorectal cancer: a multicenter retrospective study.
    BMC Cancer. 2022;22:390.
    PubMed     Abstract available

  283. UIL SH, Coupe VMH, Bril H, Meijer GA, et al
    KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer.
    BMC Cancer. 2022;22:372.
    PubMed     Abstract available

  284. CHAUVIN A, Bergeron D, Vencic J, Levesque D, et al
    Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells.
    BMC Cancer. 2022;22:363.
    PubMed     Abstract available

  285. OLENIUS T, Koskenvuo L, Koskensalo S, Lepisto A, et al
    Long-term survival among colorectal cancer patients in Finland, 1991-2015: a nationwide population-based registry study.
    BMC Cancer. 2022;22:356.
    PubMed     Abstract available

  286. RASCHZOK N, Stintzing S, Heinemann V, Rauch G, et al
    FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
    BMC Cancer. 2022;22:359.
    PubMed     Abstract available

  287. YANG L, Li W, Lu Z, Lu M, et al
    Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment.
    BMC Cancer. 2022;22:355.
    PubMed     Abstract available

    March 2022
  288. IYER DN, Foo DC, Lo OS, Wan TM, et al
    MiR-509-3p is oncogenic, targets the tumor suppressor PHLPP2, and functions as a novel tumor adjacent normal tissue based prognostic biomarker in colorectal cancer.
    BMC Cancer. 2022;22:351.
    PubMed     Abstract available

  289. JO MK, Moon CM, Kim EJ, Kwon JH, et al
    Suppressive effect of alpha-mangostin for cancer stem cells in colorectal cancer via the Notch pathway.
    BMC Cancer. 2022;22:341.
    PubMed     Abstract available

  290. SANDER C, Frydrychowicz C, Prasse G, Taubenheim S, et al
    The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series.
    BMC Cancer. 2022;22:336.
    PubMed     Abstract available

  291. BLAD N, Palmqvist R, Karling P
    Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study.
    BMC Cancer. 2022;22:315.
    PubMed     Abstract available

  292. ZHOU H, Nong Y, Zhu Y, Liang Y, et al
    Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma.
    BMC Cancer. 2022;22:314.
    PubMed     Abstract available

  293. HOYDAHL O, Edna TH, Xanthoulis A, Lydersen S, et al
    Octogenarian patients with colon cancer - postoperative morbidity and mortality are the major challenges.
    BMC Cancer. 2022;22:302.
    PubMed     Abstract available

  294. LI Y, Wu G, Zhang Y, Han B, et al
    Log odds of positive lymph nodes as a novel prognostic predictor for colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2022;22:290.
    PubMed     Abstract available

  295. PELLAT A, Boutron I, Ravaud P
    Assessment of transparency and selective reporting of interventional trials studying colorectal cancer.
    BMC Cancer. 2022;22:278.
    PubMed     Abstract available

  296. WANG Y, Shen L, Wan J, Zhang H, et al
    Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH).
    BMC Cancer. 2022;22:274.
    PubMed     Abstract available

  297. YANG M, Davis TB, Pflieger L, Nebozhyn MV, et al
    An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    BMC Cancer. 2022;22:256.
    PubMed     Abstract available

  298. VATANDOUST S, Wattchow D, Sposato L, Michael MZ, et al
    A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.
    BMC Cancer. 2022;22:222.
    PubMed     Abstract available

    February 2022
  299. YU H, Huang T, Feng B, Lyu J, et al
    Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis.
    BMC Cancer. 2022;22:210.
    PubMed     Abstract available

  300. POURSHEIKHANI A, Abbaszadegan MR, Kerachian MA
    Long non-coding RNA AC087388.1 as a novel biomarker in colorectal cancer.
    BMC Cancer. 2022;22:196.
    PubMed     Abstract available

  301. KNUDSEN MD, Kvaerner AS, Botteri E, Holme O, et al
    Lifestyle predictors for inconsistent participation to fecal based colorectal cancer screening.
    BMC Cancer. 2022;22:172.
    PubMed     Abstract available

  302. SADAHIRO S, Sakamoto K, Tsuchiya T, Takahashi T, et al
    Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
    BMC Cancer. 2022;22:170.
    PubMed     Abstract available

  303. REDVERS N, Wilkinson M, Fischer C
    Colorectal cancer community engagement: a qualitative exploration of American Indian voices from North Dakota.
    BMC Cancer. 2022;22:158.
    PubMed     Abstract available

  304. LIU XY, Kang B, Cheng YX, Yuan C, et al
    The short-term and oncologic outcomes of younger VS older colorectal cancer patients undergoing primary surgery: a propensity score matching analysis.
    BMC Cancer. 2022;22:153.
    PubMed     Abstract available

  305. WANG G, Wang F, Meng Z, Wang N, et al
    Uncovering potential genes in colorectal cancer based on integrated and DNA methylation analysis in the gene expression omnibus database.
    BMC Cancer. 2022;22:138.
    PubMed     Abstract available

  306. ZHOU S, Jiang Y, Pei W, Liang J, et al
    Prognostic significance of lateral pelvic lymph node dissection for middle-low rectal cancer patients with lateral pelvic lymph node metastasis: a propensity score matching study.
    BMC Cancer. 2022;22:136.
    PubMed     Abstract available

    January 2022
  307. PFAB C, Abgaryan A, Danzer B, Mourtada F, et al
    Ceftazidime and cefepime antagonize 5-fluorouracil's effect in colon cancer cells.
    BMC Cancer. 2022;22:125.
    PubMed     Abstract available

  308. KUO YH, You JF, Hung HY, Chin CC, et al
    Number of negative lymph nodes with a positive impact on survival of stage III colon cancer; a retrospective observation study for right side and left side colon.
    BMC Cancer. 2022;22:126.
    PubMed     Abstract available

  309. GU J, Li Y, Yu J, Hu M, et al
    A risk scoring system to predict the individual incidence of early-onset colorectal cancer.
    BMC Cancer. 2022;22:122.
    PubMed     Abstract available

  310. ZHANG QW, Dai ZH, Wang XY, Gao YJ, et al
    Influence of early colorectal cancer component on the positive margins after endoscopic resection: a retrospective study.
    BMC Cancer. 2022;22:120.
    PubMed     Abstract available

  311. MOJICA CM, Gunn R, Pham R, Miech EJ, et al
    An observational study of workflows to support fecal testing for colorectal cancer screening in primary care practices serving Medicaid enrollees.
    BMC Cancer. 2022;22:106.
    PubMed     Abstract available

  312. DE LOOPER M, Smets EMA, Schouten BC, Bolle S, et al
    The Patient Navigator: Can a systematically developed online health information tool improve patient participation and outcomes related to the consultation in older patients newly diagnosed with colorectal cancer?
    BMC Cancer. 2022;22:109.
    PubMed     Abstract available

  313. ZHAI Y, Bai W, Zhou J, Dong Q, et al
    Effect of tumour size ratio on liver recurrence-free survival of patients undergoing hepatic resection for colorectal liver metastases.
    BMC Cancer. 2022;22:103.
    PubMed     Abstract available

  314. GOODARZI G, Mozaffari H, Raeisi T, Mehravar F, et al
    Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.
    BMC Cancer. 2022;22:89.
    PubMed     Abstract available

  315. KONG D, Li G, Yang Z, Cheng S, et al
    Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes.
    BMC Cancer. 2022;22:84.
    PubMed     Abstract available

  316. MATSUBAYASHI H, Higashigawa S, Kiyozumi Y, Oishi T, et al
    Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses.
    BMC Cancer. 2022;22:73.
    PubMed     Abstract available

  317. BABIC T, Dragicevic S, Miladinov M, Krivokapic Z, et al
    SMAD4-201 transcript as a putative biomarker in colorectal cancer.
    BMC Cancer. 2022;22:72.
    PubMed     Abstract available

  318. SASSANO M, Mariani M, Quaranta G, Pastorino R, et al
    Polygenic risk prediction models for colorectal cancer: a systematic review.
    BMC Cancer. 2022;22:65.
    PubMed     Abstract available

  319. CHILOIRO G, Cusumano D, Boldrini L, Romano A, et al
    THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy.
    BMC Cancer. 2022;22:67.
    PubMed     Abstract available

  320. BENNEDSEN ALB, Cai L, Hasselager RP, Ozcan AA, et al
    An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
    BMC Cancer. 2022;22:62.
    PubMed     Abstract available

  321. REN F, Li B, Wang C, Wang Y, et al
    Iodine-125 seed represses the growth and facilitates the apoptosis of colorectal cancer cells by suppressing the methylation of miR-615 promoter.
    BMC Cancer. 2022;22:49.
    PubMed     Abstract available

  322. HOSEINI B, Rahmatinejad Z, Goshayeshi L, Bergquist R, et al
    Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry.
    BMC Cancer. 2022;22:48.
    PubMed     Abstract available

  323. YIN J, Wang H, Hong Y, Ren A, et al
    Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer.
    BMC Cancer. 2022;22:44.
    PubMed     Abstract available

  324. SHOKAR NK, Salinas J, Dwivedi A
    Mediators of screening uptake in a colorectal cancer screening intervention among Hispanics.
    BMC Cancer. 2022;22:37.
    PubMed     Abstract available

  325. CIUCA A, Moldovan R, Baban A
    Mapping psychosocial interventions in familial colorectal cancer: a rapid systematic review.
    BMC Cancer. 2022;22:8.
    PubMed     Abstract available

  326. KASAHARA K, Enomoto M, Udo R, Tago T, et al
    Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study.
    BMC Cancer. 2022;22:20.
    PubMed     Abstract available

  327. CHEN C, Yi W, Zeng ZF, Wang QX, et al
    Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery.
    BMC Cancer. 2022;22:7.
    PubMed     Abstract available

    December 2021
  328. KHODAVERDI N, Zeighami H, Jalilvand A, Haghi F, et al
    High frequency of enterotoxigenic Bacteroides fragilis and Enterococcus faecalis in the paraffin-embedded tissues of Iranian colorectal cancer patients.
    BMC Cancer. 2021;21:1353.
    PubMed     Abstract available

  329. OKI E, Shinto E, Shimokawa M, Yamaguchi S, et al
    Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
    BMC Cancer. 2021;21:1332.
    PubMed     Abstract available

  330. LI R, Wang Q, Zhang B, Yuan Y, et al
    Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases.
    BMC Cancer. 2021;21:1333.
    PubMed     Abstract available

    Gut microbiome and its role in colorectal cancer.
    BMC Cancer. 2021;21:1325.
    PubMed     Abstract available

  332. YAN C, Yang H, Chen L, Liu R, et al
    Clinical significance of mucinous component in colorectal adenocarcinoma: a propensity score-matched study.
    BMC Cancer. 2021;21:1286.
    PubMed     Abstract available

    November 2021
  333. MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
    Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
    BMC Cancer. 2021;21:1272.
    PubMed     Abstract available

  334. ZHANG P, Xu J, Zhang H, Liu XY, et al
    Identification of TRPV4 as a novel target in invasiveness of colorectal cancer.
    BMC Cancer. 2021;21:1264.
    PubMed     Abstract available

  335. JACOB S, Bosch F, Schoenberg MB, Pretzsch E, et al
    Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis.
    BMC Cancer. 2021;21:1243.
    PubMed     Abstract available

  336. MCILVANNA E, Linden GJ, Craig SG, Lundy FT, et al
    Fusobacterium nucleatum and oral cancer: a critical review.
    BMC Cancer. 2021;21:1212.
    PubMed     Abstract available

  337. SATO Y, Fu Y, Liu H, Lee MY, et al
    Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response.
    BMC Cancer. 2021;21:1222.
    PubMed     Abstract available

  338. LI JY, Huang XZ, Gao P, Song YX, et al
    Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data.
    BMC Cancer. 2021;21:1214.
    PubMed     Abstract available

  339. YANG C, Huang S, Cao F, Zheng Y, et al
    A lipid metabolism-related genes prognosis biomarker associated with the tumor immune microenvironment in colorectal carcinoma.
    BMC Cancer. 2021;21:1182.
    PubMed     Abstract available

    October 2021
  340. YAMAMOTO S, Nagashima K, Kawakami T, Mitani S, et al
    Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
    BMC Cancer. 2021;21:1159.
    PubMed     Abstract available

  341. MURDOCH J, Varley A, McCulloch J, Jones M, et al
    Implementing supportive exercise interventions in the colorectal cancer care pathway: a process evaluation of the PREPARE-ABC randomised controlled trial.
    BMC Cancer. 2021;21:1137.
    PubMed     Abstract available

  342. UEMURA M, Ikeda M, Handa R, Danno K, et al
    The efficiency of (18)F-FDG-PET/CT in the assessment of tumor response to preoperative chemoradiation therapy for locally recurrent rectal cancer.
    BMC Cancer. 2021;21:1132.
    PubMed     Abstract available

  343. SCHLIEMANN D, Ramanathan K, Matovu N, O'Neill C, et al
    The implementation of colorectal cancer screening interventions in low-and middle-income countries: a scoping review.
    BMC Cancer. 2021;21:1125.
    PubMed     Abstract available

  344. LIU T, Li W, Zhang Y, Siyin ST, et al
    Associations between hepatitis B virus infection and risk of colorectal Cancer: a population-based prospective study.
    BMC Cancer. 2021;21:1119.
    PubMed     Abstract available

  345. GORGEC B, Hansen I, Kemmerich G, Syversveen T, et al
    Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study.
    BMC Cancer. 2021;21:1116.
    PubMed     Abstract available

  346. SHIMOKAWA M, Hayashi T, Nishimura J, Satoh T, et al
    Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
    BMC Cancer. 2021;21:1111.
    PubMed     Abstract available

  347. CHRISTAKOUDI S, Tsilidis KK, Evangelou E, Riboli E, et al
    Association of body-shape phenotypes with imaging measures of body composition in the UK Biobank cohort: relevance to colon cancer risk.
    BMC Cancer. 2021;21:1106.
    PubMed     Abstract available

  348. OVERS A, Flammang M, Hervouet E, Bermont L, et al
    The detection of specific hypermethylated WIF1 and NPY genes in circulating DNA by crystal digital PCR is a powerful new tool for colorectal cancer diagnosis and screening.
    BMC Cancer. 2021;21:1092.
    PubMed     Abstract available

    September 2021
  349. KONG W, Li H, Xie L, Cui G, et al
    LncRNA MCF2L-AS1 aggravates the malignant development of colorectal cancer via targeting miR-105-5p/RAB22A axis.
    BMC Cancer. 2021;21:1069.
    PubMed     Abstract available

  350. BEDRIKOVETSKI S, Dudi-Venkata NN, Kroon HM, Seow W, et al
    Artificial intelligence for pre-operative lymph node staging in colorectal cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1058.
    PubMed     Abstract available

  351. JAFARI NASAB S, Ghanavati M, Rafiee P, Bahrami A, et al
    A case-control study of Dietary Approaches to Stop Hypertension (DASH) diets, colorectal cancer and adenomas among Iranian population.
    BMC Cancer. 2021;21:1050.
    PubMed     Abstract available

  352. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available

    August 2021
  353. BISSONNETTE RP, Cesario RM, Goodenow B, Shojaei F, et al
    The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    BMC Cancer. 2021;21:969.
    PubMed     Abstract available

  354. YASUI M, Ohue M, Noura S, Miyoshi N, et al
    Exploratory analysis of lateral pelvic sentinel lymph node status for optimal management of laparoscopic lateral lymph node dissection in advanced lower rectal cancer without suspected lateral lymph node metastasis.
    BMC Cancer. 2021;21:911.
    PubMed     Abstract available

    July 2021
  355. YODER AK, Lakomy DS, Dong Y, Raychaudhury S, et al
    The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study.
    BMC Cancer. 2021;21:776.
    PubMed     Abstract available

    June 2021
  356. LIANG Y, Zhu Y, Lin H, Zhang S, et al
    The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study.
    BMC Cancer. 2021;21:729.
    PubMed     Abstract available

  357. DHAKA B, Sabarinathan R
    Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
    BMC Cancer. 2021;21:669.
    PubMed     Abstract available

    May 2021
  358. SHARMA V, Sharma A, Raina V, Dabkara D, et al
    Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
    BMC Cancer. 2021;21:630.
    PubMed     Abstract available

  359. LI H, Yang L, Lai Y, Wang X, et al
    Genetic alteration of Chinese patients with rectal mucosal melanoma.
    BMC Cancer. 2021;21:623.
    PubMed     Abstract available

  360. TALBOT A, O'Donovan E, Berkley E, Nolan C, et al
    The contribution of Lynch syndrome to early onset malignancy in Ireland.
    BMC Cancer. 2021;21:617.
    PubMed     Abstract available

  361. CHEN R, Wang L, Zhao Q, Li Z, et al
    Platelet-to-lymphocyte ratio and C-reactive protein as markers for colorectal polyp histological type.
    BMC Cancer. 2021;21:556.
    PubMed     Abstract available

  362. ABRAHAMSSON H, Meltzer S, Hagen VN, Johansen C, et al
    Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer.
    BMC Cancer. 2021;21:535.
    PubMed     Abstract available

  363. YUKIMOTO R, Uemura M, Tsuboyama T, Hata T, et al
    Efficacy of positron emission tomography in diagnosis of lateral lymph node metastases in patients with rectal Cancer: a retrospective study.
    BMC Cancer. 2021;21:520.
    PubMed     Abstract available

  364. TYCIAKOVA S, Valova V, Svitkova B, Matuskova M, et al
    Overexpression of TNFalpha induces senescence, autophagy and mitochondrial dysfunctions in melanoma cells.
    BMC Cancer. 2021;21:507.
    PubMed     Abstract available

  365. ZHAO J, Zhu J, Sun R, Huang C, et al
    Primary tumor resection improves prognosis of unresectable carcinomas of the transverse colon including flexures with liver metastasis: a preliminary population-based analysis.
    BMC Cancer. 2021;21:503.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.